Pegylated interferon for the treatment of high-risk essential thrombocythemia.
Mesa
Ruben
R
Division of Hematology and Internal Medicine, Division of Hematopathology, Cancer Center Statistics Unit, Mayo Clinic, Rochester, USA. mesa.ruben@mayo.edu
D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010976:Platelet Count; D011994:Recombinant Proteins; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins